AR882 + xanthine oxidase inhibitor

AR882 + XOI is an investigational combination therapy for the treatment of gout, specifically for patients with a history of uncontrolled gout and visible tophi who have failed uricase therapy. AR882 (pozdeutinurad) is a novel, potent, and selective small molecule inhibitor of the urate transporter 1 (URAT1), targeting renal tubular reabsorption of uric acid to increase its excretion. XOI refers to xanthine oxidase inhibitors—a class of drugs (e.g., allopurinol, febuxostat) that decrease uric acid synthesis by inhibiting xanthine oxidase. The combination aims for dual urate-lowering (decreased production via XOI, increased excretion via URAT1 inhibition), with clinical trials evaluating efficacy in reducing serum uric acid and tophus burden, and safety in patients with refractory gout. The primary developer is Arthrosi Therapeutics, and the regimen is under study in Phase 2 and 3 trials[1][2][3][4][5][6].

Other names

pozdeutinurad + xanthine oxidase inhibitor